Oncodesign Offers Comprehensive Collection of Patient-Derived Colorectal Tumor Models
Oncodesign
announced today that the company has acquired exclusive commercialization rights to distribute the world’s most comprehensive collection of human colorectal cancer models directly developed from patient’s tumors. Oncodesign’s clients can now access the entire collection to evaluate therapeutic compounds in house or to carry out preclinical studies with Oncodesign. This new collection has integrated Oncodesign’s Chi-Mice(R) platform, designed to provide preclinical models from human samples. The Chi-Mice(R) platform includes both reconstituted human immune system models on NSG/NOG mice and models xenografted with patient-derived tumors.
“This collection is the result of a five year research program, and is the most comprehensive worldwide in terms of the range of genetic heterogeneity and characterization. It marks a breakthrough in the evaluation of colorectal cancer therapies,” explained Philippe Genne, president and CEO of Oncodesign. “The CReMEC collection ensures low-passage experimental models to fit the clinical reality. This is all the more relevant since preclinical research usually relies on cell lines that may be many years old, grown in tissue culture and then grafted onto mice. Cell lines may drift into different genetic profiles and are not reliable enough to evaluate anticancer therapies.”
CReMEC brings together skills from world-class French institutes, three pharmaceutical companies, and Oncodesign
as project leader. The EUR 5.4 million program has been developed to meet industrial requirements and strict guidelines were observed from conception to characterization. A full range of characterization is available with each model. Clinical, molecular, pharmacological and histological data have been collected and gathered in a dedicated database, in parallel with a biobank.
Oncodesign says the consortium is considering the development of a dedicated national platform. The challenge is to provide patient-derived cancer models for any cancer pathology to meet unsatisfied needs in cancer research.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
